MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

Inicio・Lista de Acciones・Lisata Therapeutics

L
Lisata Therapeutics

Cerrado

1.93 -3.98

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

1.9

Máximo

1.96

Métricas clave
By Trading Economics
Empleados	26

Dividendos
By Dow Jones
Próximas Ganancias	26 feb 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	-5.9M 14M
Apertura anterior	5.91
Cierre anterior	1.93

Lisata Therapeutics Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

10 ene 2026, 00:16 UTC

Adquisiciones, fusiones, absorciones

Edwards Lifesciences Drops Merger With JenaValve

11 ene 2026, 23:46 UTC

Charlas de Mercado

Gold Rises Amid Geopolitical Risks -- Market Talk

11 ene 2026, 23:35 UTC

Charlas de Mercado

Oil Rises Amid Middle East Tensions -- Market Talk

11 ene 2026, 23:25 UTC

Ganancias

Stock Futures Drift Lower With Bank Earnings, CPI on Tap -- Barrons.com

11 ene 2026, 22:05 UTC

Charlas de Mercado

Iron Ore Outlook Weighed by Soft China Steel Markets, Rising Supply -- Market Talk

10 ene 2026, 12:00 UTC

Adquisiciones, fusiones, absorciones

Copper Is the Prize in Mining Megadeals -- WSJ

10 ene 2026, 09:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

10 ene 2026, 09:20 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Basic Materials Roundup: Market Talk

10 ene 2026, 09:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

9 ene 2026, 22:18 UTC

Charlas de Mercado

Changes Needed for Exxon Mobil to Return to Venezuela -- Market Talk

9 ene 2026, 21:50 UTC

Charlas de Mercado

Energy & Utilities Roundup: Market Talk

9 ene 2026, 21:50 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Basic Materials Roundup: Market Talk

9 ene 2026, 21:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

9 ene 2026, 21:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

9 ene 2026, 21:43 UTC

Ganancias

Adquisiciones, fusiones, absorciones

These Stocks Moved the Most Today: Oklo, Vistra, Opendoor, Intel, GM, Revolution Medicines, Tilray, and More -- Barrons.com

9 ene 2026, 20:39 UTC

Charlas de Mercado

GE Vernova Seen With Rising Concern of Overcapacity -- Market Talk

9 ene 2026, 20:38 UTC

Charlas de Mercado

U.S. Natural Gas Falls on Loose Supply Outlook -- Market Talk

9 ene 2026, 20:36 UTC

Adquisiciones, fusiones, absorciones

Cathie Wood's ARK Invest Takes a New Stake in Broadcom -- and Sold Another Hot Stock -- Barrons.com

9 ene 2026, 20:30 UTC

Charlas de Mercado

Oil Makes Weekly Gains in Geopolitically Driven Trade -- Market Talk

9 ene 2026, 20:15 UTC

Charlas de Mercado

Chevron Seen With Modest Opportunity to Boost Venezuela Oil Production -- Market Talk

9 ene 2026, 20:07 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

9 ene 2026, 20:07 UTC

Charlas de Mercado

Goldman Sachs' Pivot from Consumer Lending Seen as Positive -- Market Talk

9 ene 2026, 19:58 UTC

Adquisiciones, fusiones, absorciones

Merck in Talks to Buy Revolution Medicines for Around $30 Billion -- WSJ

9 ene 2026, 19:42 UTC

Charlas de Mercado

Adobe Seen With Weak Competitive Position Compared to Rivals -- Market Talk

9 ene 2026, 19:38 UTC

Adquisiciones, fusiones, absorciones

Wolters Kluwer Acquires StandardFusion >WTKWY

9 ene 2026, 19:31 UTC

Ganancias

Qualcomm Stock Falls After Downgrade. The Apple Supplier Has an iPhone Problem. -- Barrons.com

9 ene 2026, 19:28 UTC

Ganancias

Apple Stock Set to Break Brutal Losing Streak. Why It Remains Evercore's 'Top Pick.' -- Barrons.com

9 ene 2026, 18:30 UTC

Charlas de Mercado

U.S. Oil Rig Count Falls by 3 to 409 -- Market Talk

9 ene 2026, 18:23 UTC

Charlas de Mercado

Reports of Canada Oil Sector's Demise Are Premature -- Market Talk

9 ene 2026, 17:20 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Basic Materials Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Lisata Therapeutics Esperado

Consenso

By TipRanks

0 ratings

Comprar

Mantener

Vender

De acuerdo con 0 analistas que ofrecen calificaciones bursátiles a para Lisata Therapeutics Dist en los últimos 3 meses.

Finanzas

Acerca de Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.